메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

NYSE Content Advisory: Pre-Market Update + NYSE Takes Its Bell on the Road to JPMorgan's Healthcare Event

NEW YORK, Jan. 12, 2026 -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content Advisory: Pre-Market Update + NYSE Takes Its Bell on the Road to JPMorgan’s Healthcare Event JD Durkin delivers the pre-market update on January 12th Stocks are down Monday morning after the Justice Department opened a criminal investigation into Federal Reserve Chair Jerome Powell. Despite White House pressure to lower interest
- 황정호 기자
- 2026-01-12 22:00
BostonGene Recognized by Frost & Sullivan for 2025 Global Technology Innovation Leadership in AI-Driven Precision Oncology Solutions

[ 메디채널 김갑성 기자 ] Reshaping the Global Drug Development Landscape with the Industry's Only Natively AI-Powered Omnimodal Foundation Model for Tumor and Immune Biology SAN ANTONIO, Jan. 12, 2026 -- Frost & Sullivan is pleased to announce that BostonGene has been recognized for 2025 Global Technology Innovation Leadership in the AI-driven Precision Oncology Solutions sector for its outstanding achievements in Technology Innovation Leadership. This recognition highlights BostonGene's consistent leadership in driving measurable outcomes, strengthening its market position, and deliverin
- 김갑성 기자
- 2026-01-12 21:00
Major global health grant awarded to Oktopi to accelerate equitable medicine development capability worldwide.

MELBOURNE, Australia, Jan. 12, 2026 -- Oktopi has been awarded a significant grant from the Gates Foundation to advance global access to high-quality medicine development expertise, with a particular focus on supporting innovators in low- and middle-income countries (LMICs). This funding will enable Oktopi to build and expand its AI-informed knowledge and workflow engine, bringing best-practice to the critical decisions in developing medicines. The engine integrates expert-derived taxonomies, evidence expectations, and decision pathways to increase efficiency and the probability of su
- 김갑성 기자
- 2026-01-12 21:00
Novo Nordisk's GLP‑1 RA--A Modern Treatment for Obesity Management--is Linked to Lower Household Spending on Alcohol and Tobacco

[ 메디채널 김갑성 기자 ] Real-world data analysis suggests that families with at least one member using Novo Nordisk's GLP‑1 RA for weight management tend to reduce spending on alcohol and cigarettes. JAKARTA, Indonesia, Jan. 12, 2026 -- At the international scientific congress ObesityWeek® held late last year in Atlanta, United States, Novo Nordisk presented findings from a real-world analysis of grocery spending data from more than 200,000 households.[1] The analysis found that households with at least one person using Novo Nordisk's GLP‑1 RA for weight management showed a year-on-year
- 김갑성 기자
- 2026-01-12 18:29
알라마 바이오사이언스, 목표액 초과 전환사채 자금 조달 완료…경영진 확대

[ 메디채널 김갑성 기자 ] T. 로우 프라이스 투자운용과 브레이드웰 LP가 신규 투자자로 참여 스티븐 윌리엄스 박사, 최고과학책임자로 합류 레베카 챔버스와 프랭크 위트니 박사를 이사로 영입 프리몬트, 캘리포니아주, 2026년 1월 12일 -- 질병의 조기 진단을 앞당기는 데 전념하고 있는 단백질체학 분야 선도기업 알라마 바이오사이언스(Alamar Biosciences, 이하 '알라마')가 전환사채 발행을 통해 5000만 달러 이상의 신규 자본을 유치했다고 발표했다. 이번 발행에는 초기 목표 금액보다 많은 투자금이 몰렸으며, [ 메디채널 김갑성 기자 ] T. 로우 프라이스 투자운용(T. Rowe Price Investment Management, Inc.)과 브레이드웰 LP(Braidwell LP)가 자문하는 계좌들이 신규 투자자로 합류했다. 이와 함께 일루미나 벤처스(Illumina Ventures)와 샌즈 캐피털(Sands Capital) 등 기존 투자자들도 후속 투자에 나섰다. 알라마는 이번에 조달한 자금으로 정밀 단백질체학 플랫폼의 지속적인 상업적 발전을 지원할 예정이다. 알라마의 창립자이
- 김갑성 기자
- 2026-01-12 18:29
Dr.stretch Malaysia partners with NHA athlete Saif Nordin, brings elite mobility and performance to all Malaysians

KUALA LUMPUR, Malaysia, Jan. 12, 2026 -- Dr.stretch Malaysia, the country's leading specialised assisted-stretching brand, is proud to announce a new partnership with national fencer Saif Nordin, one of Malaysia's most promising young athletes who is also a News Hub Asia (NHA) athlete. This collaboration supports Dr.stretch's mission to make professional mobility, recovery, and performance care accessible to Malaysians of all ages and activity levels. Data suggests that across Malaysia, poor mobility and insufficient recovery practices are quietly becoming an economic challenge
- 황정호 기자
- 2026-01-12 17:40
Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib (LNK01001) in Rheumatoid Arthritis

[ 메디채널 김갑성 기자 ] HANGZHOU, China, SHANGHAI and BOSTON, Jan. 12, 2026 -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical stage innovative drug development company focused on developing innovative therapies for immune and inflammatory diseases, today announced positive topline results from its Phase III clinical trial evaluating zemprocitinib (LNK01001) in patients with moderate to severe active rheumatoid arthritis (RA). The study met its primary and key secondary efficacy endpoints, demonstrating statistically significant improvements
- 김갑성 기자
- 2026-01-12 08:00
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors FREMONT, Calif., Jan. 12, 2026 -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by [ 메디채널 김갑성 기자 ] T. Rowe Price Investment Man
- 김갑성 기자
- 2026-01-12 05:15
Pierre Fabre Laboratories and Iktos Announce an Integrated AI-Driven Drug Discovery Collaboration in Oncology

CASTRES, France and PARIS, Jan. 9, 2026 -- Pierre Fabre Laboratories and Iktos, a global leader in Artificial Intelligence (AI) and Robotics on drug discovery, today announced an integrated drug discovery collaboration to identify and develop novel small-molecule drug candidates in oncology. This initiative reflects both companies' commitment to advancing oncology research by integrating complementary strengths across computational design, medicinal chemistry, biology, medical science and preclinical development. Under the terms of the agreement, Iktos will leverage its AI-driv
- 김갑성 기자
- 2026-01-09 15:00
Ribo Life Science (06938.HK) Successfully Lists on the Main Board of the Hong Kong Stock Exchange

HONG KONG, Jan. 9, 2026 -- Ribo Life Science Co., Ltd. ("Ribo" or the "Company", stock code: 06938.HK), a leading company in small interfering RNA (siRNA) therapeutics, today successfully listed on the Main Board of Hong Kong Stock Exchange, marking a significant milestone in the capitalization of Chinese biopharmaceutical enterprises in the siRNA field and injecting new momentum into the industry. In its global offering, Ribo issued a total of 31,610,400 shares at an offer price of HKD 57.97 per share, raising gross proceeds of over 1.8 billion Hong Kong do
- 황정호 기자
- 2026-01-09 13:07

이전

41 42 43 44 45 46 47 48 49 50

많이 본 기사

최근기사

2026-03-03_TUE

2026-03-02_MON

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 03월 03일 03시 40분